Brokerages Set Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) PT at $10.00

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) has been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $10.00.

A number of brokerages recently weighed in on ATHE. Craig Hallum set a $2.00 price target on Alterity Therapeutics in a research note on Tuesday, August 11th. JonesTrading assumed coverage on shares of Alterity Therapeutics in a report on Tuesday, June 30th. They issued a “buy” rating and a $16.00 target price for the company. Zacks Research raised shares of Alterity Therapeutics to a “hold” rating in a research report on Wednesday, June 17th. UBS Group set a $12.00 price target on shares of Alterity Therapeutics in a report on Tuesday, August 11th. Finally, LADENBURG THALM/SH SH initiated coverage on shares of Alterity Therapeutics in a research report on Tuesday, June 16th. They issued a “buy” rating and a $10.00 price target for the company.

Alterity Therapeutics Stock Down 1.5%

NASDAQ ATHE opened at $4.05 on Friday. Alterity Therapeutics has a 1 year low of $2.66 and a 1 year high of $5.89. The business’s fifty day moving average is $4.71 and its two-hundred day moving average is $4.32.

Alterity Therapeutics (NASDAQ:ATHE) last issued its earnings results on Thursday, July 30th. The company reported ($0.28) earnings per share (EPS) for the quarter. The company had revenue of $0.31 million during the quarter. On average, equities analysts anticipate that Alterity Therapeutics will post -0.12 earnings per share for the current fiscal year.

Institutional Trading of Alterity Therapeutics

A hedge fund recently raised its stake in Alterity Therapeutics stock. Greenleaf Trust lifted its holdings in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) by 93.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 62,000 shares of the company’s stock after buying an additional 30,000 shares during the period. Greenleaf Trust owned about 0.70% of Alterity Therapeutics worth $333,000 as of its most recent SEC filing. 2.14% of the stock is currently owned by institutional investors and hedge funds.

Alterity Therapeutics Company Profile

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.